Abstract
Originalsprog | Engelsk |
---|---|
Tidsskrift | Cancer |
Vol/bind | 106 |
Udgave nummer | 5 |
Sider (fra-til) | 1130-9 |
Antal sider | 9 |
ISSN | 0008-543X |
DOI | |
Status | Udgivet - 2006 |
Bibliografisk note
Keywords: Adolescent; Adult; Aged; Case-Control Studies; Cell Movement; Female; Glycoproteins; Humans; L-Lactate Dehydrogenase; Lectins; Male; Melanoma; Middle Aged; Multivariate Analysis; Prognosis; Skin Neoplasms; Survival Analysis; Tumor Markers, BiologicalAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. / Schmidt, Henrik; Johansen, Julia Sidenius; Gehl, Julie; Geertsen, Poul F; Fode, Kirsten; von der Maase, Hans.
I: Cancer, Bind 106, Nr. 5, 2006, s. 1130-9.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma
AU - Schmidt, Henrik
AU - Johansen, Julia Sidenius
AU - Gehl, Julie
AU - Geertsen, Poul F
AU - Fode, Kirsten
AU - von der Maase, Hans
N1 - Keywords: Adolescent; Adult; Aged; Case-Control Studies; Cell Movement; Female; Glycoproteins; Humans; L-Lactate Dehydrogenase; Lectins; Male; Melanoma; Middle Aged; Multivariate Analysis; Prognosis; Skin Neoplasms; Survival Analysis; Tumor Markers, Biological
PY - 2006
Y1 - 2006
N2 - BACKGROUND: YKL-40 is a growth factor for connective tissue cells and stimulates migration of endothelial cells. Cancer cells, macrophages, and neutrophils secrete YKL-40. Its function in cancer is unknown. High serum YKL-40 levels have been associated with a poor prognosis in patients with several solid tumors. The prognostic impact of serum YKL-40 in metastatic melanoma was evaluated. METHODS: YKL-40 was measured in serial serum samples from 110 patients with metastatic melanoma obtained immediately before and during treatment and from 245 healthy subjects. RESULTS: Patients had higher serum YKL-40 values than healthy subjects (P < 0.001). Pretreatment serum YKL-40 was elevated in 45% of the patients and correlated to site of metastases (P = 0.03) and poor performance status (P = 0.002). Multivariate Cox analysis showed that serum YKL-40 (hazard ratio [HR] = 1.9; 95% confidence interval [CI], 1.2-2.8; P = 0.004) and serum lactate dehydrogenase (LDH) (HR = 1.9; 95% CI, 1.2-2.9; P = 0.004) were independent prognostic factors for survival. A combination variable of elevated serum YKL-40 and LDH quadrupled the risk of early death (HR = 4.4; 95% CI, 2.5-7.7; P < 0.001) compared with patients with normal levels. The combination of YKL-40 and LDH had a stronger prognostic impact than the American Joint Committee on Cancer (AJCC) Stage IV classification. Furthermore, serum samples were available from 12 patients during followup. In 9 of 11 patients a significant increase in serum YKL-40 was observed together with disease progression. In one patient with a lasting complete response, serum YKL-40 remained normal. CONCLUSIONS: An elevated serum YKL-40 was an independent prognostic factor for poor survival in patients with metastatic melanoma. When combining serum YKL-40 and LDH, patients could be separated into three prognostic groups based on the number of elevated biomarkers. The findings should be validated in an independent study.
AB - BACKGROUND: YKL-40 is a growth factor for connective tissue cells and stimulates migration of endothelial cells. Cancer cells, macrophages, and neutrophils secrete YKL-40. Its function in cancer is unknown. High serum YKL-40 levels have been associated with a poor prognosis in patients with several solid tumors. The prognostic impact of serum YKL-40 in metastatic melanoma was evaluated. METHODS: YKL-40 was measured in serial serum samples from 110 patients with metastatic melanoma obtained immediately before and during treatment and from 245 healthy subjects. RESULTS: Patients had higher serum YKL-40 values than healthy subjects (P < 0.001). Pretreatment serum YKL-40 was elevated in 45% of the patients and correlated to site of metastases (P = 0.03) and poor performance status (P = 0.002). Multivariate Cox analysis showed that serum YKL-40 (hazard ratio [HR] = 1.9; 95% confidence interval [CI], 1.2-2.8; P = 0.004) and serum lactate dehydrogenase (LDH) (HR = 1.9; 95% CI, 1.2-2.9; P = 0.004) were independent prognostic factors for survival. A combination variable of elevated serum YKL-40 and LDH quadrupled the risk of early death (HR = 4.4; 95% CI, 2.5-7.7; P < 0.001) compared with patients with normal levels. The combination of YKL-40 and LDH had a stronger prognostic impact than the American Joint Committee on Cancer (AJCC) Stage IV classification. Furthermore, serum samples were available from 12 patients during followup. In 9 of 11 patients a significant increase in serum YKL-40 was observed together with disease progression. In one patient with a lasting complete response, serum YKL-40 remained normal. CONCLUSIONS: An elevated serum YKL-40 was an independent prognostic factor for poor survival in patients with metastatic melanoma. When combining serum YKL-40 and LDH, patients could be separated into three prognostic groups based on the number of elevated biomarkers. The findings should be validated in an independent study.
U2 - 10.1002/cncr.21678
DO - 10.1002/cncr.21678
M3 - Journal article
C2 - 16456816
VL - 106
SP - 1130
EP - 1139
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 5
ER -